Table 2.
Univariate analysis of variables for the prediction of survival outcomes in training cohort.
| Variables | Overall survival | Cancer-specific survival | Metastasis-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | |
| Gender (Male vs. Female) | 0.887 | 0.569–1.382 | 0.595 | 0.892 | 0.541–1.471 | 0.655 | 1.062 | 0.687–1.643 | 0.786 |
| Age (>65 vs. ≤65 years) | 2.025 | 1.276–3.214 | 0.003* | 1.780 | 1.069–2.966 | 0.027* | 1.526 | 1.002–2.325 | 0.049* |
| BMI (≥25 vs. <25) | 0.414 | 0.089–0.680 | 0.007* | 0.417 | 0.191–0.909 | 0.028* | 0.434 | 0.232–0.812 | 0.009* |
| ASA grade (≥3 vs. <3) | 1.541 | 0.993–2.391 | 0.054 | 1.355 | 0.816–2.251 | 0.241 | 1.155 | 0.739–1.804 | 0.528 |
| Hydronephrosis (Yes vs. No) | 1.543 | 0.970–2.457 | 0.067 | 1.895 | 1.088–3.300 | 0.024* | 1.991 | 1.241–3.195 | 0.004* |
| Surgical approach (laparoscopic vs. open) | 0.696 | 0.431–1.125 | 0.140 | 0.722 | 0.423–1.231 | 0.232 | 0.707 | 0.452–1.106 | 0.129 |
| SIRI (≥1.36 vs. <1.36) | 2.298 | 1.515–3.487 | <0.001* | 2.736 | 1.684–4.445 | <0.001* | 1.950 | 1.311–2.901 | 0.001* |
| NLR (≥2.53 vs. <2.53) | 2.718 | 1.726–4.280 | <0.001* | 2.385 | 1.445–3.937 | 0.001* | 1.573 | 1.053–2.350 | 0.027* |
| PLR (≥126.88 vs. <126.88) | 2.780 | 1.780–4.341 | <0.001* | 2.673 | 1.617–4.419 | <0.001 | 1.844 | 1.231–2.763 | 0.003* |
| MLR (≥0.35 vs. <0.35) | 2.162 | 1.436–3.254 | <0.001* | 2.141 | 1.350–3.397 | 0.001* | 1.692 | 1.142–2.507 | 0.009* |
| Anemia (Yes vs. No) | 1.913 | 1.270–2.882 | 0.002* | 0.262 | 0.063–1.089 | 0.065 | 1.791 | 1.210–2.650 | 0.004* |
| Hypoproteinemia (Yes vs. No) | 2.618 | 1.476–4.643 | 0.001* | 1.802 | 1.136–2.859 | 0.012* | 1.907 | 1.063–3.421 | 0.030* |
| CKD stage | |||||||||
| CKD 1 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 |
| CKD 2–3 | 2.888 | 1.054–7.911 | 0.039* | 2.931 | 0.917–9.370 | 0.070 | 2.486 | 1.006–6.141 | 0.048* |
| CKD 4–5 | 6.039 | 2.007–18.176 | 0.001* | 6.097 | 1.728–21.514 | 0.005* | 4.753 | 1.734–13.025 | 0.002* |
| Tumor size (≥3 vs. <3) | 1.600 | 1.061–2.412 | 0.025* | 1.061 | 0.971–1.159 | 0.190 | 1.564 | 1.056–2.318 | 0.026* |
| Tumor site | |||||||||
| Pelvicalyceal | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 |
| Ureter | 1.405 | 0.910–2.170 | 0.125 | 1.606 | 0.988–2.613 | 0.056 | 1.576 | 1.042–2.384 | 0.031* |
| Both | 1.701 | 0.679–4.259 | 0.257 | 2.345 | 0.923–5.959 | 0.073 | 2.232 | 1.106–4.905 | 0.046* |
| Multifocality (Yes vs. No) | 1.640 | 1.023–2.628 | 0.040* | 1.749 | 1.036–2.952 | 0.036* | 1.380 | 0.866–2.198 | 0.175 |
| Pathologic T stage | |||||||||
| pT1 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 |
| pT2 vs. pT1 | 1.352 | 0.695–2.630 | 0.374 | 2.241 | 0.918–5.470 | 0.076 | 1.982 | 1.083–3.630 | 0.027* |
| pT3 vs. pT1 | 4.108 | 2.221–7.597 | <0.001* | 6.988 | 3.029–16.125 | <0.001* | 3.391 | 1.840–6.247 | <0.001* |
| pT4 vs. pT1 | 13.121 | 6.761–25.464 | <0.001* | 25.422 | 10.709–60.346 | <0.001* | 9.626 | 5.056–18.329 | <0.001* |
| N stage (N1 vs. N0) | 7.359 | 4.435–12.211 | <0.001* | 8.945 | 5.235–15.283 | <0.001* | 5.291 | 3.240–8.641 | <0.001* |
| Tumor grade (≥3 vs. <3) | 2.641 | 1.277–5.463 | 0.009* | 4.443 | 1.619–12.191 | 0.004* | 2.244 | 1.227–4.104 | 0.009* |
| LVI (Yes vs. No) | 4.830 | 3.116–7.485 | <0.001* | 6.248 | 4.004–10.321 | <0.001* | 3.848 | 2.508–5.905 | <0.001* |
| Adjuvant therapy (Yes vs. No) | 2.842 | 1.746–4.625 | <0.001* | 3.614 | 2.158–6.053 | <0.001* | 3.543 | 2.214–5.672 | <0.001* |
*
Statistically significant.